Shin YR reported that KRAS mutation in CRC patients was correlated with N stage (53), the gross morphology of the tumor, the axial length of the tumor, and the ratio of the axial to longitudinal dimensions of the tumor (p = 0.0064, p < 0.0001, p = 0.0003, and p = 0.0090, respectively). This evidence concerns the gene KRAS and colorectal carcinoma.